At a glance
A PEG-modified MGF-related construct discussed in tissue research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
PEG attachment is intended to change a molecule’s exposure and handling. That modification also means PEG-MGF must be evaluated as its own construct rather than assuming equivalence with native IGF-related peptides.[1]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source cites experimental repair and proliferation findings. Identify whether a paper tested the PEG-modified material or a different MGF preparation.[3][4][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of PEG MGF.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 2 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~0.667 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg | 30 units (0.30 mL) |
| Weeks 3–4 | 300 mcg | 45 units (0.45 mL) |
| Weeks 5–6 | 400 mcg | 60 units (0.60 mL) |
| Weeks 7–8 | 500 mcg | 75 units (0.75 mL) |
Frequency: Inject once daily subcutaneously. Pegylation extends MGF’s half-life, allowing systemic once-daily SC dosing instead of frequent intramuscular injections[5]. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection volumes easy to measure accurately on standard insulin syringes.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support muscle recovery and regeneration through MGF’s satellite cell activation and local growth factor signaling[5][6].
- Schedule: Daily subcutaneous injections for 8 weeks (extend to 12–16 weeks if desired).
- Dose Range: 200–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 2 mg vial (~0.667 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach based on preclinical research protocols[3][5].
- Start: 200 mcg daily; increase by ~100 mcg every 2 weeks as tolerated.
- Target: 400–500 mcg daily by Weeks 5–8.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8 weeks; optional extension to 12–16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and bioactivity[10].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7][8][9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and tissue irritation.
- Always use a new sterile needle and syringe for each injection; dispose of sharps in proper containers.
Materials & quantity planning
Source materials checklist · 2 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (PEG MGF, 2 mg each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 17 vials
- 16 weeks ≈ 24 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (17 vials): 51 mL → 6 × 10 mL bottles
- 16 weeks (24 vials): 72 mL → 8 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 2 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
- 03
- 05
Source document
Cureus — Peptide Therapy (News article on Mechano-Growth Factor) (opens in a new tab)www.cureus.com
Back to overview ↑ - 08
Source document
Cleveland Clinic — Lipohypertrophy: Symptoms, Causes, Treatment & Prevention (opens in a new tab)my.clevelandclinic.org
Back to overview ↑ - 10
Source document
Bachem — Handling and Storage Guidelines for Peptides (opens in a new tab)www.bachem.com
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.